The volume of shares traded in a session often gets a passing mention in the financial press until a

SOPHiA GENETICS SA (NASDAQ: SOPH - Get Free Report) reached a new 52-week high during trading on Tue

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Sophia Genetics (NASDAQ:SOPH) wi

BTIG analyst Mark Massaro maintains Sophia Genetics (NASDAQ:SOPH) with a Buy and raises the price

SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcript

SOPHiA GENETICS NASDAQ: SOPH reported second-quarter revenue growth of 27% and raised its full-year

Sophia Genetics (NASDAQ:SOPH) raises FY2026 sales outlook from $92.000 million-$94.000 million to $9

Sophia Genetics (NASDAQ:SOPH) reported quarterly losses of $(0.30) per share which missed the analys

BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global

SOPHiA GENETICS (NASDAQ:SOPH) today announced a new global collaboration to develop, validate, and d

BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today ann

BOSTON and ROLLE, Switzerland, July 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a globa

Wall Street analysts change ratings on top stocks. See full changes on analyst ratings page. SCHW, M

Top Wall Street analysts upgraded URBN, GPN, YETI. See what analysts think of SCHW stock.

Top analysts changed outlook on top names. For all changes, incl. upgrades/downgrades/initiations, s

HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on Sophia Genetics (NAS

Shareholders adopt all proposals, co-founder Dr. Jurgi Camblong elected as Executive Chairman of the

BOSTON and ROLLE, Switzerland, June 19, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a globa

SOPHiA GENETICS is approaching an inflection point in precision medicine, leveraging AI-driven genom

(Editor’s note: The future prices of benchmark tracking ETFs and the headline were updated in the st

U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining over 100 points

U.S. stock futures mostly higher, Nasdaq futures gain 100+ points. Sophia Genetics (SOPH) falls afte

U.S. stock futures trading higher. CarMax, Sophia Genetics, Jabil, La-Z-Boy, and Safe Bulkers in foc

SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares PR Newswire BOST

BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a globa

SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, announced today the

BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a globa

SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, today confirmed, ahe

Ross Muken to assume the role of Chief Executive Officer effective July 1, 2026; Co-founder Dr. Jurg

SOPHiA GENETICS (NASDAQ: SOPH) today announced that the company has signed a Memorandum of Understan

SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center Aim to Establish Precision Medicine Hub f

Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.

LONDON, May 13, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in Ai-driven pr

SOPHiA GENETICS SA (SOPH) Q1 2026 Earnings Call Transcript

BOSTON and ROLLE, Switzerland, May 5, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global

Sophia Genetics (NASDAQ:SOPH) affirms FY2026 sales outlook from $92.000 million-$94.000 million to $

Sophia Genetics (NASDAQ:SOPH) reported quarterly losses of $(0.27) per share which missed the analys

SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced that

BTIG analyst Mark Massaro maintains Sophia Genetics (NASDAQ:SOPH) with a Buy and raises the price

2026 Financial OutlookBased on information as of today, SOPHiA GENETICS is reaffirming the following

SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced the

Guggenheim analyst Subbu Nambi maintains Sophia Genetics (NASDAQ:SOPH) with a Buy and raises the

Executive Transition PlanSOPHiA GENETICS today announced the promotion of Ross Muken to Chief Execut

Full Year 2026 GuidanceBased on information as of today, SOPHiA GENETICS is providing the following

Fourth Quarter 2025 Preliminary Unaudited Financial ResultsRevenue of at least $21 million, represen